Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

References

• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Yau T, Kang Y-K, Kim T-Y, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564–e204564. doi:10.1001/jamaoncol.2020.4564
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Mauri FA, Spina P, et al. Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. Br J Cancer. 2019;120(11):1033–1036. doi:10.1038/s41416-019-0466-x
   PubMed Web of Science ®Google Scholar
• Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer≤ 2 cm: results from two Western centers. Hepatology. 2013;57(4):1426–1435. doi:10.1002/hep.25832
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–1354. doi:10.1016/S1470-2045(15)00198-9
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab+ chemotherapy vs. placebo+ chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol. 2021;32(9):1198–1200. doi:10.1016/j.annonc.2021.06.014
   Web of Science ®Google Scholar
• Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020;38(22):2476–2487. doi:10.1200/JCO.20.00201
   PubMed Web of Science ®Google Scholar
• Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–1661. doi:10.1038/s41591-018-0198-0
   PubMed Web of Science ®Google Scholar
• Forde PM, Anagnostou V, Sun Z, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27(11):1910–1920. doi:10.1038/s41591-021-01541-0
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, et al. Abstract CT003: nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Res. 2021;81(13_Supplement):CT003–CT003. doi:10.1158/1538-7445.AM2021-CT003
   Web of Science ®Google Scholar
• Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219–229. doi:10.1016/S2468-1253(21)00385-X
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208–218. doi:10.1016/S2468-1253(21)00427-1
   PubMed Web of Science ®Google Scholar
• Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2(9):891–903. doi:10.1038/s43018-021-00234-4
   PubMedGoogle Scholar
• Pinato DJ, Fessas P, Sapisochin G, Marron TU. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma. Hepatology. 2020;74(1):483–490.
   Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–514. doi:10.1038/s41591-020-01224-2
   PubMed Web of Science ®Google Scholar
• Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–461. doi:10.1038/s41591-019-0357-y
   PubMed Web of Science ®Google Scholar
• Rusch VW, Chaft JE, Johnson B, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): initial results from a multicenter study (LCMC3). Am Soc Clin Oncol. 2018;36(15_suppl):8541. doi:10.1200/JCO.2018.36.15_suppl.8541
   Web of Science ®Google Scholar
• Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, Phase 2 trial. medRxiv. 2020;26:5140–5152.
   Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Losic B, Craig AJ, Villacorta-Martin C, et al. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun. 2020;11(1):291. doi:10.1038/s41467-019-14050-z
   PubMed Web of Science ®Google Scholar
• Nault JC, Villanueva A. Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res. 2015;21(8):1786–1788. doi:10.1158/1078-0432.CCR-14-2602
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411. doi:10.1001/jamaoncol.2019.2187
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi:10.1038/nature22079
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668–1674. doi:10.1200/JCO.2017.75.6270
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947–955. doi:10.1097/SLA.0000000000000710
   PubMed Web of Science ®Google Scholar
• Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62(2):440–451. doi:10.1002/hep.27745
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):8500. doi:10.1200/JCO.2021.39.15_suppl.8500
   Web of Science ®Google Scholar
• Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395(10236):1558–1568. doi:10.1016/S0140-6736(20)30417-7
   PubMed Web of Science ®Google Scholar
• Garris CS, Arlauckas SP, Kohler RH, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity. 2018;49(6):1148–1161 e7. doi:10.1016/j.immuni.2018.09.024
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–1399. doi:10.1158/2159-8290.CD-16-0577
   PubMed Web of Science ®Google Scholar
• Tang F, Tie Y, Tu C, et al. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199–223. doi:10.1002/ctm2.24
   PubMed Web of Science ®Google Scholar
• Jia R, Zhou M, Tuttle CSL, et al. Immune capacity determines outcome following surgery or trauma: a systematic review and meta-analysis. Eur J Trauma Emerg Surg. 2020;46(5):979–991. doi:10.1007/s00068-019-01271-6
   PubMed Web of Science ®Google Scholar
• Fitzgerald BG, Galsky MD, Marron TU. The cutting edge: leveraging pre-surgical immunotherapy trials to understand therapeutic mechanisms. Immuno-Oncol Insights. 2022;3(3):81–91. doi:10.18609/ioi.2022.011
   Google Scholar
• Cheng X, Zhang H, Hamad A, et al. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol. 2022. doi:10.1016/j.semcancer.2022.01.006
   Web of Science ®Google Scholar
• Bakos O, Lawson C, Rouleau S, et al. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86. doi:10.1186/s40425-018-0398-7
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:6477. doi:10.1126/science.aax0182
   Web of Science ®Google Scholar
• Remark R, Merghoub T, Grabe N, et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci Immunol. 2016;1(1):aaf6925. doi:10.1126/sciimmunol.aaf6925
   PubMed Web of Science ®Google Scholar
• Goltsev Y, Samusik N, Kennedy-Darling J, et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell. 2018;174(4):968–981. e15. doi:10.1016/j.cell.2018.07.010
   PubMed Web of Science ®Google Scholar
• Giesen C, Wang HAO, Schapiro D, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014;11(4):417–422. doi:10.1038/nmeth.2869
   PubMed Web of Science ®Google Scholar
• Lin J-R, Izar B, Wang S, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018;7. doi:10.7554/eLife.31657
   Web of Science ®Google Scholar
• Zhuang X. Spatially resolved single-cell genomics and transcriptomics by imaging. Nat Methods. 2021;18(1):18–22. doi:10.1038/s41592-020-01037-8
   PubMed Web of Science ®Google Scholar
• Merritt CR, Ong GT, Church SE, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38(5):586–599. doi:10.1038/s41587-020-0472-9
   PubMed Web of Science ®Google Scholar
• Ståhl PL, Salmén F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78–82. doi:10.1126/science.aaf2403
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750–765. e17. doi:10.1016/j.cell.2017.04.014
   PubMed Web of Science ®Google Scholar
• Leader AM, Grout JA, Chang C, et al. CITEseq analysis of non-small-cell lung cancer lesions reveals an axis of immune cell activation associated with tumor antigen load and TP53 mutations. bioRxiv. 2020. doi:10.1101/2020.07.16.207605
   Google Scholar
• Giladi A, Cohen M, Medaglia C, et al. Dissecting cellular crosstalk by sequencing physically interacting cells. Nat Biotechnol. 2020;38(5):629–637. doi:10.1038/s41587-020-0442-2
   PubMed Web of Science ®Google Scholar
• Rose SA, Wroblewska A, Dhainaut M, et al. A microRNA expression and regulatory element activity atlas of the mouse immune system. Nat Immunol. 2021;22(7):914–927. doi:10.1038/s41590-021-00944-y
   PubMed Web of Science ®Google Scholar
• Caushi JX, Zhang J, Ji Z, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021;596(7870):126–132. doi:10.1038/s41586-021-03752-4
   PubMed Web of Science ®Google Scholar
• Hamon P, Magen A, Cohen M, et al. Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma. Cancer Res. 2021;81:64.
   PubMed Web of Science ®Google Scholar
• Hegde S, Leader AM, Merad M. MDSC: markers, development, states, and unaddressed complexity. Immunity. 2021;54(5):875–884. doi:10.1016/j.immuni.2021.04.004
   PubMed Web of Science ®Google Scholar
• Ordentlich P. Clinical evaluation of colony-stimulating factor 1 receptor inhibitors. Semin Immunol. 2021;54:101514. doi:10.1016/j.smim.2021.101514
   PubMed Web of Science ®Google Scholar
• Williet N, Dubreuil O, Boussaha T, et al. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. World J Gastroenterol. 2011;17(17):2255. doi:10.3748/wjg.v17.i17.2255
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Ikeda M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). Am Soc Clin Oncol. 2020;30:v286–v287.
   Google Scholar
• Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol. 2015;63(1):83–92. doi:10.1016/j.jhep.2015.01.023
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42–e50. doi:10.1016/S1470-2045(13)70334-6
   PubMed Web of Science ®Google Scholar
• Xia Y, Wang P, Pu L, et al. Preliminary Efficacy and Safety of Perioperative Treatment of Camrelizumab Combined With Apatinib in Resectable Hepatocellular Carcinoma (HCC): A Prospective Phase II Study. Wolters Kluwer Health; 2021.
   Google Scholar
• Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant. 2020;20(1):220–230. doi:10.1111/ajt.15576
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–456. doi:10.1038/s41586-021-03362-0
   PubMed Web of Science ®Google Scholar